Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion

By V. Gorboulev, A. Schürmann, V. Vallon, H. Kipp, A. Jaschke, D. Klessen, Alexandra Friedrich, S. Scherneck, T. Rieg, R. Cunard and 13 more. Diabetes, 2011

643 citations recorded by the source corpus.

To clarify the physiological role of Na+-d-glucose cotransporter SGLT1 in small intestine and kidney, Sglt1−/− mice were generated and characterized phenotypically. After gavage of d-glucose, small intestinal glucose absorption across the brush-border membrane (BBM) via SGLT1 and GLUT2 were analyzed. Glucose-induced secretion of insulinotropic hormone (GIP) and glucagon-like peptide 1 (GLP-1) in wild-type and Sglt1−/− mice were compared. The impact of SGLT1 on renal glucose handling was investigated by micropuncture studies. It was observed that Sglt1−/− mice developed a glucose-galactose malabsorption syndrome but thrive normally when fed a glucose-galactose–free diet. In wild-type mice, passage of d-glucose across the intestinal BBM was predominantly mediated by SGLT1, independent the glucose load. High glucose concentrations increased the amounts of SGLT1 and GLUT2 in the BBM, and SGLT1 was required for upregulation of GLUT2. SGLT1 was located in luminal membranes of cells immunopositive for GIP and GLP-1, and Sglt1−/− mice exhibited reduced glucose-triggered GIP and GLP-1 levels. In the kidney, SGLT1 reabsorbed ∼3% of the filtered glucose under normoglycemic conditions. The data indicate that SGLT1 is 1) pivotal for intestinal mass absorption of d-glucose, 2) triggers the glucose-induced secretion of GIP and GLP-1, and 3) triggers the upregulation of GLUT2.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/a8db8d4ea645a03d823c291307801295e892a3fb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Lawrence Lin
2. Kathleen M. Giacomini
3. R. Kim
4. S. Yee

Citations in the corpus

• SLC Transporters as Therapeutic Targets: Emerging Opportunities (2015, positive): “…• Several inhibitors of SGLT1 and/or SGLT2 have been approved to treat type 2 diabetes, including canagliflozin, dapagliflozin and empagliflozin 187,188 ; tofogliflozin and ipragliflozin are approved for use in Japan • A PET imaging probe, [ 99m Tc]-pertechnetate, is being studied for imaging and…”